2
Indication details
- Control Arm
- Placebo
- FDA Therapeutic Indication
- Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours with disease progression in adults
- Tumour Type
-
Endocrine Tumours
- Tumour Sub-type
- Neuroendocrine Tumour - Pancreatic
- Tumour Stage
- Unresectable or metastatic
- NCT Number
- NCT00428597
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approved
- EMA Approval
- EMA approved
Primary Outcome(s)
- Primary Outcome(s)
- PFS (crossover allowed)
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 5.5 months
- PFS Gain
- 5.9 months
- PFS HR
- 0.42 (0.26-0.66)
- OS Control
- 29.1 months
- OS Gain
- 9.5 months
- OS HR
- 0.73 (0.50-1.06) not significant
Adjustments
- QoL Comment
-
No QoL benefit
Score (after adjustments)
- Preliminary non-curative score
-
3
- Only improved PFS mature data shows no OS advantage and no improved QoL
- Only improved PFS mature data shows no OS advantage and no improved QoL
- Non-curative score
-
2
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 151
- Scorecard version
- 1
- Issue date
- 12.03.2020
- Last update
- 20.03.2024
Legend
Information about symbols, abbrevations and color codes
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include: